Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference
Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference
FOSTER CITY, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced the Company management will be presenting at the Canaccord Genuity 44th Annual Growth Conference taking place on August 13-15, 2024 in Boston, MA.
加利福尼亞州福斯特城，2024年8月8日（環球新聞社）-- Apollomics公司 （納斯達克:APLM）（「Apollomics」或「公司」），一家開發多個研究難治和抗藥癌症治療方案的晚期臨床生物製藥公司，今天宣佈公司管理層將參加於2024年8月13-15日在馬薩諸塞州波士頓舉行的Canaccord Genuity第44屆年度增長大會。
Canaccord Genuity 44th Annual Growth Conference
加拿大皇家證券第44屆增長會議
Format: Company presentation
Presentation Date & Time: Tuesday, August 14, 2024 at 9:30 am ET
Location: InterContinental Boston Hotel
Presenter: Matthew Plunkett, PhD, Chief Financial Officer of Apollomics
Webcast: Click here
格式：公司演示
演示日期和時間：2024年8月14日星期二，美國東部時間上午9:30
地點：波士頓洲際酒店
演講者：Apollomics首席財務官Matthew Plunkett，博士
網絡直播：點擊這裏
Management will be available for one-on-one meetings during the conference. Interested investors should contact their Canaccord Genuity representative to request meetings. A link to access company presentation, when available, will be posted to Company website on the Events page under the Investors section.
公司管理層在會議期間將提供一對一會議。有興趣的投資者應聯繫他們的Canaccord Genuity代表安排會議。當公司演示文稿可用時，將在公司網站的投資者分區的活動頁面下發布訪問鏈接。
About Apollomics Inc.
關於 Apollomics公司
Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics' lead programs include its core product, vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia and other hematologic cancers, which is currently in Phase 1 and Phase 3 clinical trials in China. For more information, please visit .
Apollomics Inc.是一家創新的臨床生物製藥公司，專注於發現和開發腫瘤療法，具有成爲與其他治療選擇結合的潛力，以利用免疫系統並針對特定的分子通路抑制癌症。Apollomics的主要項目包括其核心產品vebreltinib（APL-101），它是一種選擇性強的c-Met抑制劑，用於治療非小細胞肺癌和其他攜帶c-Met改變的晚期腫瘤，目前正在美國進行2期多隊列臨床試驗；以及uproleselan（APL-106），一種特異性的E-Selectin拮抗劑，具有作爲標準化療的輔助用藥用於治療急性髓性白血病和其他血液系統腫瘤的潛力，目前正在中國進行1期和3期臨床試驗。欲了解更多信息，請訪問。
Investor Contact:
投資者聯繫人：
Eric Ribner
LifeSci Advisors, LLC
(646) 751-4363
eric@lifesciadvisors.com
艾瑞·裏伯納
LifeSci Advisors，LLC
(646) 751-4363
eric@lifesciadvisors.com
譯文內容由第三人軟體翻譯。